KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Ferrero, S; Rossi, D; Rinaldi, A; Bruscaggin, A; Spina, V; Eskelund, C W; Evangelista, A; Moia, R; Kwee, I; Dahl, C; Di Rocco, A; Stefoni, V; Diop, F; Favini, C; Ghione, P; Mahmoud, A M; Schipani, M; Kolstad, A; Barbero, D; Novero, D; Paulli, M; Zamò, A; Jerkeman, M; Gomez Da Silva, M; Santoro, A; Molinari, A; Ferreri, A; Gronbaek, K; Piccin, A; Cortellazzo, S; Bertoni, F; Ladetto, M; Gaidano, G